Device / Technology News

RSS

ContextVision launches GOPView iRVUltra product at 2011 ECR annual meeting

ContextVision is pleased to announce the showcasing and market launch of a second new product at the 2011 European Congress of Radiology in Vienna.

3 Mar 2011

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Scientists develop simple home-based blood pressure measuring device for diabetics

Many people get stressed when they visit the doctor, leading to blood pressure readings higher than normal. It's called "White Coat Syndrome." And since two-thirds of diabetics suffer from high blood pressure, getting accurate readings is crucial to getting proper care for them.

3 Mar 2011

ContextVision launches two breast cancer diagnostic imaging solutions at ECR 2011

ContextVision, the software imaging partner for the most recognized medical imaging manufacturers worldwide, today introduced two innovative solutions at the 2011 European Congress of Radiology.

3 Mar 2011

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces its featured products at the European Society of Radiology's annual meeting being held in Vienna, Austria from March 3 - 7, 2011.

3 Mar 2011

PositiveID reaches chemistry milestone in glucose-sensing RFID microchip development

PositiveID Corporation announced today that it has reached an important chemistry milestone in the development of its GlucoChip, glucose-sensing RFID microchip.

3 Mar 2011

MicroConstants completes installation, qualification of new Xevo TQ-S tandem mass spectrometer

MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization in San Diego, California, announces today that it has successfully completed the installation and qualification of a new Xevo TQ-S tandem mass spectrometer from Waters Corporation.

3 Mar 2011

Children with ASD can benefit from interactive computer program

Children with autism spectrum disorders are better able to recognize faces, facial expressions and emotions with the help of an interactive computer program called FaceSay, according to newly published research from psychologists at the University of Alabama at Birmingham.

3 Mar 2011

IBM announces new Patient Empowerment System

Today IBM announced the next evolution of the patient portal, significantly expanding the types of information, alerts, recommendations and interactive coaching healthcare providers can offer to their patients online.

3 Mar 2011

Alternative intraoral appliance to treat obstructive sleep apnea

AZ-TMJ is once again leading the way in innovative and effective treatments for patients with obstructive sleep apnea (OSA). Approximately one in five adults have at least mild sleep apnea, and one in 15 are classified as moderate sleep apnea sufferers. Sleep apnea is a disorder where a person's ability to breathe is impaired, resulting in a restless sleep and oftentimes snoring.

3 Mar 2011

Patients with end-stage renal disease who opt for PD experience no greater risk of catheter infection

Patients with end-stage renal disease who opt for peritoneal dialysis experience no greater risk of catheter infection than those who undergo hemodialysis, a retrospective study at UT Southwestern Medical Center has found.

3 Mar 2011

Naviscan launches PEM breast cancer scanner in Europe

Naviscan, Inc., announces the European launch of the Naviscan Positron Emission Mammography scanner at two prestigious radiology conferences in Vienna.

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

Portola, Accumetrics sign agreement to develop and supply VerifyNow System

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an agreement with Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow System and VerifyNowTests for use in clinical trials.

3 Mar 2011

Scientists devise new on-line calculator to predict food allergies in children

An on-line calculator that predicts, within seconds, the presence of the three major food allergies in children has been developed by researchers at University College Cork.

2 Mar 2011

ASU receives W. M. Keck $1 million grant to build next-generation 3D imaging microscope

The W. M. Keck Foundation has awarded Arizona State University a $1 million grant to the team of scientists led by Deirdre Meldrum, Ph.D., at the Biodesign Institute.

2 Mar 2011

TOF positron emission tomography scans can improve cancer detection

For the first time, quantitative-not qualitative-data analysis has demonstrated that time-of-flight positron emission tomography scans can improve cancer detection.

2 Mar 2011

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Calypte Biomedical Corporation, a developer, manufacturer and marketer of HIV diagnostic tests, today announced successful completion of internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.

2 Mar 2011

FDA clears Meridian's illumigene C. difficile molecular amplification test

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new pediatric claim for its illumigene C. difficile molecular amplification test. C. difficile is a bacterium that is frequently associated with antibiotic therapy often causing diarrhea and, in severe cases, a life-threatening inflammation of the colon.

2 Mar 2011

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.

2 Mar 2011